Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

New research shows that fecal transplants may boost the effectiveness of cancer immunotherapy drugs called PD-1 inhibitors.

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive ...

However, some patients relapse or present with de novo metastatic disease. For those not recently exposed to platinum-based therapies, the standard of care includes gemcitabine, cisplatin, and the ...

About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body’s ability to ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy ...

The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...